Related Experiment Video
Updated: Aug 5, 2025

Optical Control of a Neuronal Protein Using a Genetically Encoded Unnatural Amino Acid in Neurons
Published on: March 28, 2016
Recoding of Nonsense Mutation as a Pharmacological Strategy
Gazmend Temaj1, Pelin Telkoparan-Akillilar2, Nexhibe Nuhii3
1Faculty of Pharmacy, College UBT, 10000 Prishtina, Kosovo.
Abstract:
Approximately 11% of genetic human diseases are caused by nonsense mutations that introduce a premature termination codon (PTC) into the coding sequence. The PTC results in the production of a potentially harmful shortened polypeptide and activation of a nonsense-mediated decay (NMD) pathway. The NMD pathway reduces the burden of unproductive protein synthesis by lowering the level of PTC mRNA. There is an endogenous rescue mechanism that produces a full-length protein from a PTC mRNA. Nonsense suppression therapies aim to increase readthrough, suppress NMD, or are a combination of both strategies. Therefore, treatment with translational readthrough-inducing drugs (TRIDs) and NMD inhibitors may increase the effectiveness of PTC suppression. Here we discuss the mechanism of PTC readthrough and the development of novel approaches to PTC suppression. We also discuss the toxicity and bioavailability of therapeutics used to stimulate PTC readthrough.
Related Concept Videos
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Mutations
In-vitro Mutagenesis
RNA Editing
Point and Frameshift Mutations
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...

